MedTrace Logo

CLEAR-B: Cancer Landscape - Early Adjuvant Retrospective Registry - Breast Cancer

NCT05870813 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2023-05-23

No results posted yet for this study

Summary

This is a non-interventional retrospective cohort study of premenopausal patients with HR+/HER2- breast cancer who are treated in the adjuvant setting with either Tamoxifen, Tamoxifen + Ovarial Function Suppression or Aromatase inhibitor + Ovarial Function Suppression.

Conditions

Sponsors & Collaborators

  • AGO Breast Study Group e.V.

    collaborator UNKNOWN

  • Novartis Pharmaceuticals

    collaborator INDUSTRY

  • Institut fuer Frauengesundheit

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-10
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05870813 on ClinicalTrials.gov